{
  "event": {
    "ticker": "PYPD",
    "company": "PolyPid Ltd.",
    "drug": "D-PLEX100",
    "application_type": "NDA",
    "indication": "Prevention of surgical site infections in patients undergoing abdominal colorectal surgery (the pivotal trial enrolled patients with incisions longer than 20 cm)",
    "pdufa_date": "2026-11-28"
  },
  "display": {
    "company": "PolyPid",
    "drug": "D-PLEX100",
    "indication_en": "Surgical site infection prevention",
    "indication_zh": "预防手术部位感染"
  },
  "probability_approval": 0.7,
  "confidence": "low",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "The pivotal trial met its primary endpoint and all three key secondary endpoints",
      "direction": "+",
      "step": "medium",
      "evidence": "SHIELD II was a randomized Phase 3 trial of D-PLEX100 added to standard care versus standard care alone in elective colorectal resection; the primary analysis covered patients with an incision longer than 20 cm (405 versus 393). The primary endpoint, a composite of incisional infection, re-intervention at the incision or death from any cause within 30 days, occurred in 10.9% (95% CI 8.0 to 14.3) versus 18.1% (95% CI 14.4 to 22.2), a difference of -7.2 percentage points (95% CI -12.1 to -2.3; p=0.0039). Incisional infection alone, judged by a blinded independent committee, was 3.8% versus 9.5% (difference -5.8 points, 95% CI -9.3 to -2.3; p=0.0013). The composite in all 975 randomized patients (incisions over 7 cm) was 11.1% versus 17.4% (p=0.0047), and the share of patients with an ASEPSIS wound score above 20 was 2.0% versus 5.6% (p=0.0103). There is no public record of a peer-reviewed publication of SHIELD II as of 5 October 2026; the figures are the sponsor's entries in the trial registry.",
      "source": "ClinicalTrials.gov NCT04411199 (SHIELD II), results first posted 2026-07-13: https://clinicaltrials.gov/study/NCT04411199?tab=results; PolyPid 6-K exhibit 99.1, 2025-06-09 (SHIELD II topline): https://www.sec.gov/Archives/edgar/data/1611842/000121390025052320/ea024508901ex99-1_polypid.htm"
    },
    {
      "factor": "FDA shaped the trial and agreed in advance that one pivotal trial could be enough",
      "direction": "+",
      "step": "small",
      "evidence": "By the company's account: in May 2021 FDA agreed in a Type B meeting that a single pivotal Phase 3 study would be sufficient for approval in colorectal surgery, provided the results were adequate; in January 2023, after the first Phase 3 trial, FDA said its large-incision results \"may provide supportive evidence\" and recommended one additional study, a role SHIELD II could fill; in May 2023 FDA agreed to the revised SHIELD II design; and in the pre-NDA minutes announced on 3 December 2025 FDA agreed that the clinical package \"appears adequate to support NDA submission and review\". The large-incision analysis of the first trial had itself been requested by FDA. D-PLEX100 holds Breakthrough Therapy designation (November 2020), Fast Track status and three Qualified Infectious Disease Product designations. In February 2026 FDA's leadership wrote that one adequate and well-controlled trial plus confirmatory evidence is now the default basis for approval. Limits: none of FDA's letters or minutes is public, and the pre-NDA wording is about whether the package can be submitted and reviewed, not whether it will be approved.",
      "source": "PolyPid 20-F for FY2024, filed 2025-02-26: https://www.sec.gov/Archives/edgar/data/1611842/000121390025017412/ea0231533-20f_polypid.htm; PolyPid 6-K exhibit 99.1, 2023-01-24 (FDA Type D feedback): https://www.sec.gov/Archives/edgar/data/1611842/000121390023004609/ea172110ex99-1_polypid.htm; PolyPid 6-K exhibit 99.1, 2025-12-03 (pre-NDA minutes): https://www.sec.gov/Archives/edgar/data/1611842/000121390025117581/ea026831301ex99-1_polypid.htm; PolyPid 20-F for FY2025, filed 2026-02-25: https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/ea0276727-20f_polypid.htm; Prasad and Makary, N Engl J Med 2026;394(8):815-7, as summarised by AMR.Solutions on 2026-03-01: https://amr.solutions/2026/03/01/fda-one-pivotal-trial-confirmatory-evidence-is-default-expectation-for-approval/"
    },
    {
      "factor": "The application was filed with no review issues flagged, and no advisory committee has been called",
      "direction": "+",
      "step": "small",
      "evidence": "PolyPid announced on 1 June 2026 that its rolling submission was complete. FDA accepted the application for filing on 27 July 2026 and, according to the company, \"did not identify any filing review issues\". The goal date of 28 November 2026 follows from priority review, but that status says little about FDA's view of the data: the law requires priority review for the first application for a product with Qualified Infectious Disease Product designation. The company has announced no advisory committee meeting on the application, and the Federal Register carries no meeting notice for the Antimicrobial Drugs Advisory Committee since June 2026. On 12 August 2026 the chief executive described the review as effective and efficient, with several rounds of communication with FDA. No mid-cycle or late-cycle meeting outcome and no labeling discussion has been disclosed. 28 November 2026 is a Saturday, two days after Thanksgiving, so FDA may act a few days earlier.",
      "source": "PolyPid 6-K exhibit 99.1, 2026-06-01 (submission completed): https://www.sec.gov/Archives/edgar/data/1611842/000121390026063169/ea029288201ex99-1.htm; PolyPid 6-K exhibit 99.1, 2026-07-29 (FDA acceptance): https://www.sec.gov/Archives/edgar/data/1611842/000121390026082564/ea029964201ex99-1.htm; PolyPid 6-K exhibit 99.1, 2026-08-12 (Q2 2026 update): https://www.sec.gov/Archives/edgar/data/1611842/000121390026088040/ea030152801ex99-1.htm; FDA guidance, Qualified Infectious Disease Product Designation Questions and Answers: https://www.fda.gov/media/148480/download; Federal Register, notices mentioning the Antimicrobial Drugs Advisory Committee, searched 2026-10-05: https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=%22Antimicrobial+Drugs+Advisory+Committee%22; PolyPid Q2 2026 results call transcript, 2026-08-12: https://www.fool.com/earnings/call-transcripts/2026/08/19/polypid-pypd-q2-2026-earnings-call-transcript/"
    },
    {
      "factor": "An earlier Phase 3 trial failed, and the successful one tests a subgroup taken from it",
      "direction": "-",
      "step": "small",
      "evidence": "The first Phase 3 trial, SHIELD I (977 patients, incisions over 10 cm), missed its primary endpoint in September 2022: 9.3% versus 12.1% (difference -2.8 points, 95% CI -6.7 to 1.0; p=0.152), with incisional infection at 6.2% versus 6.9% (p=0.62). In a pre-specified analysis of the 423 patients with incisions over 20 cm, not adjusted for multiple testing, the primary endpoint occurred in 17 of 212 (8.0%) versus 37 of 211 (17.5%), p=0.0032. SHIELD II had by then enrolled more than 200 patients under broader criteria, about 40 of them with large incisions; in 2023 it was re-designed to enrol only incisions over 20 cm. Testing a subgroup result in a new prospective trial is the accepted way to confirm it, and the result repeated. Even so, the package is one successful trial and one failed trial, with a primary p-value of 0.0039. SHIELD II also had an unblinded interim analysis of the first 430 patients, after which the sample was raised from a minimum of 624 to 800. The control arm received no placebo and the surgical team knew the assignment; wound assessors and the adjudication committee were blinded. The company's annual report for 2025, unlike the one for 2024, no longer describes the first trial.",
      "source": "ClinicalTrials.gov NCT04233424 (SHIELD I), results first posted 2025-06-22: https://clinicaltrials.gov/study/NCT04233424?tab=results; PolyPid 6-K exhibit 99.1, 2022-09-02 (SHIELD I topline): https://www.sec.gov/Archives/edgar/data/1611842/000121390022053474/ea165323ex99-1_polypid.htm; Zmora et al., SHIELD 1 randomized clinical trial, International Journal of Surgery 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC11486998/; PolyPid 20-F for FY2024, filed 2025-02-26: https://www.sec.gov/Archives/edgar/data/1611842/000121390025017412/ea0231533-20f_polypid.htm; PolyPid 6-K exhibit 99.1, 2024-12-26 (interim analysis): https://www.sec.gov/Archives/edgar/data/1611842/000121390024112468/ea022575301ex99-1_polypid.htm; ClinicalTrials.gov NCT04411199 (SHIELD II), results first posted 2026-07-13: https://clinicaltrials.gov/study/NCT04411199?tab=results; PolyPid 20-F for FY2025, filed 2026-02-25: https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/ea0276727-20f_polypid.htm"
    },
    {
      "factor": "Almost none of the pivotal-trial patients were treated in the United States",
      "direction": "-",
      "step": "small",
      "evidence": "Of the 975 patients randomized in SHIELD II, 4 were enrolled in the United States. The largest contributors were Moldova (246), Hungary (181), Serbia (135), North Macedonia (113), Romania (104), Bosnia and Herzegovina (68) and Israel (55); 973 of the 975 were White. SHIELD I had 37 US patients out of 977. FDA's rule for applications that rest on foreign data asks that the data be applicable to the US population and US medical practice, and that FDA be able to validate them, by inspection where it sees the need. Randomization was stratified by region and by type of prophylaxis (including oral antibiotics with bowel preparation), but 4 US patients cannot give a US-specific estimate of the effect. On 2 September 2026 the directors of FDA's drug and biologics centers said the agency would step up inspections of trials run abroad. Against this, FDA knew where the patients had been enrolled when it accepted the application without filing issues. Whether FDA has inspected any trial site is not public.",
      "source": "ClinicalTrials.gov NCT04411199 (SHIELD II), results first posted 2026-07-13: https://clinicaltrials.gov/study/NCT04411199?tab=results; ClinicalTrials.gov NCT04233424 (SHIELD I), results first posted 2025-06-22: https://clinicaltrials.gov/study/NCT04233424?tab=results; 21 CFR 314.106, foreign data: https://www.ecfr.gov/current/title-21/section-314.106; Hogan Lovells, 2026-09-16, on FDA's statement of 2026-09-02 about trials outside the US: https://www.hlc.com/en/publications/fda-signals-more-inspections-scrutiny-of-clinical-trials-outside-the-us; PolyPid 6-K exhibit 99.1, 2026-07-29 (FDA acceptance): https://www.sec.gov/Archives/edgar/data/1611842/000121390026082564/ea029964201ex99-1.htm"
    },
    {
      "factor": "No excess of serious harm, and fewer deaths, with D-PLEX100",
      "direction": "+",
      "step": "small",
      "evidence": "In the SHIELD II safety population (481 on D-PLEX100, 493 on standard care, followed for 60 days) there were 10 deaths (2.1%) versus 19 (3.9%), and serious adverse events in 75 patients (15.6%) versus 85 (17.2%); serious postoperative wound infection was reported in 3 versus 10. In SHIELD I deaths were 16 of 485 versus 17 of 489 and serious adverse events 69 of 478 versus 98 of 498. The active ingredient, doxycycline, has long been approved, and the application relies in part on FDA's earlier findings for it (the 505(b)(2) route). Each 5 g vial holds 54.6 mg of doxycycline and at most three vials are used (163.8 mg); the company reports minimal systemic exposure.",
      "source": "ClinicalTrials.gov NCT04411199 (SHIELD II), results first posted 2026-07-13: https://clinicaltrials.gov/study/NCT04411199?tab=results; ClinicalTrials.gov NCT04233424 (SHIELD I), results first posted 2025-06-22: https://clinicaltrials.gov/study/NCT04233424?tab=results; Zmora et al., SHIELD 1 randomized clinical trial, International Journal of Surgery 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC11486998/; PolyPid 20-F for FY2025, filed 2026-02-25: https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/ea0276727-20f_polypid.htm; PolyPid 6-K exhibit 99.1, 2026-05-13 (Q1 2026 update): https://www.sec.gov/Archives/edgar/data/1611842/000121390026055449/ea029031501ex99-1.htm"
    },
    {
      "factor": "Wound dehiscence was reported more often with D-PLEX100",
      "direction": "-",
      "step": "small",
      "evidence": "In SHIELD II, non-serious wound dehiscence was reported in 25 of 481 patients (5.2%) on D-PLEX100 versus 8 of 493 (1.6%) on standard care; incision-site erythema in 65 versus 46 and swelling in 58 versus 45. Serious wound dehiscence (2 versus 2) and wound evisceration (2 versus 2) were balanced. In SHIELD I, impaired healing was reported in 7 of 478 versus 1 of 498, and wound dehiscence in 6 versus 5. The product leaves coated beta-tricalcium phosphate particles in the closed wound. This looks more like a matter for the label than a ground for rejection, and the company describes the safety profile as good, but FDA's reading of it is not public. FDA told the company in 2023 that a product for preventing infection has the potential for wide use.",
      "source": "ClinicalTrials.gov NCT04411199 (SHIELD II), results first posted 2026-07-13: https://clinicaltrials.gov/study/NCT04411199?tab=results; ClinicalTrials.gov NCT04233424 (SHIELD I), results first posted 2025-06-22: https://clinicaltrials.gov/study/NCT04233424?tab=results; Zmora et al., SHIELD 1 randomized clinical trial, International Journal of Surgery 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC11486998/; PolyPid 6-K exhibit 99.1, 2023-01-24 (FDA Type D feedback): https://www.sec.gov/Archives/edgar/data/1611842/000121390023004609/ea172110ex99-1_polypid.htm"
    },
    {
      "factor": "First commercial product, made in the company's own sterile plant, which FDA has never cleared",
      "direction": "-",
      "step": "large",
      "evidence": "PolyPid has no approved product. D-PLEX100, a sterile powder that is mixed into a paste at the time of surgery, is made at the company's leased plant of about 22,000 square feet in Petah Tikva, Israel. The license agreement of 17 July 2026 states that PolyPid is \"currently only licensed by the Israeli Governmental Authorities for Manufacture of investigational medicinal product\" and holds no FDA authorization for commercial supply; the annual report says the plant must pass an FDA pre-approval inspection before approval. On 12 August 2026 the chief executive said FDA had been in contact about the audits expected during the review, declined to give dates, and said the company had run several mock inspections with outside consultants. As of 5 October 2026 there is no public record that the inspection has taken place, or of its outcome. The six-month priority clock leaves little time to answer inspection findings before 28 November. A regional war with Iran ran from 28 February 2026 until a deal announced on 14 June 2026, while the application was being submitted, and the annual report warns that hostilities can disrupt operations. The doxycycline supplier and any contract manufacturers are not named in public filings, and the company says it relies on a sole supplier for several raw materials.",
      "source": "PolyPid 20-F for FY2025, filed 2026-02-25: https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/ea0276727-20f_polypid.htm; License and Supply Agreement with Azurity dated 2026-07-17, exhibit 10.1 to the 6-K of 2026-07-21: https://www.sec.gov/Archives/edgar/data/1611842/000121390026079808/ea029855901ex10-1.htm; PolyPid management's discussion for the six months to 2026-06-30, 6-K exhibit 99.2, 2026-08-12: https://www.sec.gov/Archives/edgar/data/1611842/000121390026088439/ea030023101ex99-2.htm; PolyPid Q2 2026 results call transcript, 2026-08-12: https://www.fool.com/earnings/call-transcripts/2026/08/19/polypid-pypd-q2-2026-earnings-call-transcript/; PolyPid at the Lytham Partners investor conference, 2026-09-29 (transcript summary): https://www.investing.com/news/transcripts/polypid-at-lytham-partners-fda-decision-nears-for-lead-drug-93CH-4923807; Al Jazeera, 2026-06-15: https://www.aljazeera.com/news/2026/6/15/iran-us-agree-tentative-deal-to-end-war-your-questions-answered"
    },
    {
      "factor": "The plant has a clean record with Israel's regulator, and the process was validated in 2023",
      "direction": "+",
      "step": "small",
      "evidence": "Israel's Ministry of Health completed a GMP audit of the plant in September 2023 \"without any critical or major findings\" and another in September 2025, which the company calls the fourth consecutive successful inspection; the audits are recognised in the EU under the EU-Israel conformity agreement. Three process-validation batches were completed in September 2023 and placed on stability testing. The manufacturing and nonclinical sections of the application went in first, on 30 March 2026, about two months before the clinical sections, giving FDA more time with them. Prospective commercial partners, including Azurity, carried out on-site diligence at the plant, according to management. Pre-launch inventory stood at $1.4 million on 30 June 2026. An Israeli GMP certificate does not replace an FDA inspection.",
      "source": "PolyPid 20-F for FY2025, filed 2026-02-25: https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/ea0276727-20f_polypid.htm; PolyPid 20-F for FY2024, filed 2025-02-26: https://www.sec.gov/Archives/edgar/data/1611842/000121390025017412/ea0231533-20f_polypid.htm; PolyPid 6-K exhibit 99.1, 2025-09-16 (Israeli GMP inspection): https://www.sec.gov/Archives/edgar/data/1611842/000121390025087942/ea025753001ex99-1_polypid.htm; PolyPid 6-K exhibit 99.1, 2026-05-13 (Q1 2026 update): https://www.sec.gov/Archives/edgar/data/1611842/000121390026055449/ea029031501ex99-1.htm; PolyPid Q2 2026 results call transcript, 2026-08-12: https://www.fool.com/earnings/call-transcripts/2026/08/19/polypid-pypd-q2-2026-earnings-call-transcript/; PolyPid 6-K exhibit 99.1, 2026-08-12 (Q2 2026 update): https://www.sec.gov/Archives/edgar/data/1611842/000121390026088040/ea030152801ex99-1.htm"
    },
    {
      "factor": "A commercial partner paid $30 million before the decision, and launch is being prepared",
      "direction": "+",
      "step": "small",
      "evidence": "On 17 July 2026 Azurity Pharmaceuticals took US and Canadian rights, paying $15 million on signing and a further $15 million once FDA accepted the application; up to about $300 million more depends on regulatory, development and sales milestones, and a US launch is targeted for early 2027. Management says Azurity is building the sales force and that joint launch teams are at work. PolyPid filed its European application on 14 September 2026, and the EMA has validated it. With the Azurity payments the company expects to fund operations into 2028, so the review does not coincide with a need to raise money. Insider filings since March 2026 show option grants only. On the other side, PolyPid and ADVANZ PHARMA ended their 2022 European license by mutual agreement, announced on 1 October 2026; the company presents this as a chance to find a new partner. The interim accounts to 30 June 2026 still carry a going-concern warning.",
      "source": "PolyPid 6-K, 2026-07-21 (Azurity agreement): https://www.sec.gov/Archives/edgar/data/1611842/000121390026079808/ea0298559-6k_polypid.htm; PolyPid 6-K exhibit 99.1, 2026-08-12 (Q2 2026 update): https://www.sec.gov/Archives/edgar/data/1611842/000121390026088040/ea030152801ex99-1.htm; PolyPid Q2 2026 results call transcript, 2026-08-12: https://www.fool.com/earnings/call-transcripts/2026/08/19/polypid-pypd-q2-2026-earnings-call-transcript/; PolyPid 6-K exhibit 99.1, 2026-10-01 (EMA validation): https://www.sec.gov/Archives/edgar/data/1611842/000121390026105492/ea030731601ex99-1.htm; PolyPid 6-K exhibit 99.1, 2026-10-01 (ADVANZ termination): https://www.sec.gov/Archives/edgar/data/1611842/000121390026105474/ea030731501ex99-1.htm; PolyPid interim financial statements at 2026-06-30, 6-K exhibit 99.1, 2026-08-12: https://www.sec.gov/Archives/edgar/data/1611842/000121390026088439/ea030023101ex99-1.htm; SEC EDGAR filing list for PolyPid Ltd. (CIK 1611842), as of 2026-10-05: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001611842&type=&dateb=&owner=include&count=40"
    }
  ],
  "manufacturing_risk": {
    "level": "high",
    "why": "D-PLEX100 is PolyPid's first commercial product and is made in the company's own sterile plant in Petah Tikva, Israel (about 22,000 square feet; the interim accounts call it a pilot manufacturing plant). The product is a complex formulation: a polymer-lipid matrix carrying doxycycline, coated on beta-tricalcium phosphate particles and supplied as a sterile powder in 5 g vials. As of July 2026 the plant was licensed by the Israeli authorities for investigational product only and had no FDA authorization for commercial supply; an FDA pre-approval inspection is required. In its favour: four consecutive successful GMP inspections by Israel's Ministry of Health (the latest in September 2025; the 2023 audit had no critical or major findings), three process-validation batches completed in September 2023, and manufacturing sections submitted two months ahead of the clinical ones. What cannot be judged: whether FDA has inspected the plant and with what result (no public record as of 5 October 2026); who supplies the doxycycline and the sole-sourced raw materials, and their inspection history; and how the packaging contractor chosen by Azurity fits into the application. The annual report also notes that an earlier Israeli audit of a contract manufacturer's process for D-PLEX100 produced critical observations, which the company says were resolved."
  },
  "what_would_change_my_mind": [
    "Up: PolyPid or FDA discloses that the pre-approval inspection of the Petah Tikva plant is complete with no observations, or with observations that FDA has accepted as resolved.",
    "Up: the company reports labeling discussions or post-marketing commitments with FDA, the usual signs of a review heading towards approval.",
    "Down: a Form 483 with significant observations at the plant or at a supplier, or word that the inspection cannot be completed before the goal date, including because of security conditions in Israel.",
    "Down: FDA convenes an advisory committee, questions whether the Eastern European data apply to US practice, or reports data-integrity findings at high-enrolling trial sites.",
    "Date change rather than a no: FDA extends the goal date after a major amendment; the estimate would then be reassessed against the new date.",
    "Void rather than no: PolyPid withdraws the application before FDA acts."
  ],
  "summary_en": "FDA approval of D-PLEX100 in this review cycle is put at 70%, below the 76% base rate for first-time applications from smaller companies. The clinical case is solid: the pivotal SHIELD II trial cut a composite of wound infection, re-intervention and death from 18.1% to 10.9% (p=0.0039), on a design FDA agreed in advance. Manufacturing holds the estimate down. This is PolyPid's first product, made in its own sterile plant in Israel, which FDA has never cleared, and there is no public record that the pre-approval inspection has happened. Lesser concerns: an earlier Phase 3 trial failed, only 4 of 975 patients were enrolled in the United States, and wound dehiscence was more frequent with the drug.",
  "summary_zh": "FDA 在本轮审评中批准 D-PLEX100 的概率估计为 70%，低于小公司首次申请 76% 的基准。临床证据扎实：关键试验 SHIELD II 把切口感染、再次干预和死亡的复合终点发生率从 18.1% 降到 10.9%（p=0.0039），试验设计事先得到 FDA 认可。压低估计的是生产环节：这是 PolyPid 的第一个产品，由公司自己在以色列的无菌工厂生产，该厂从未获得 FDA 认可，批准前检查是否已经进行也没有公开记录。次要的顾虑有三：更早的一项 III 期试验失败；975 名患者中只有 4 名在美国入组；用药组切口裂开更多。",
  "sources": [
    "ClinicalTrials.gov NCT04411199 (SHIELD II), results first posted 2026-07-13: https://clinicaltrials.gov/study/NCT04411199?tab=results",
    "ClinicalTrials.gov NCT04233424 (SHIELD I), results first posted 2025-06-22: https://clinicaltrials.gov/study/NCT04233424?tab=results",
    "PolyPid 6-K exhibit 99.1, 2026-07-29 (FDA acceptance): https://www.sec.gov/Archives/edgar/data/1611842/000121390026082564/ea029964201ex99-1.htm",
    "PolyPid 6-K exhibit 99.1, 2026-08-12 (Q2 2026 update): https://www.sec.gov/Archives/edgar/data/1611842/000121390026088040/ea030152801ex99-1.htm",
    "PolyPid interim financial statements at 2026-06-30, 6-K exhibit 99.1, 2026-08-12: https://www.sec.gov/Archives/edgar/data/1611842/000121390026088439/ea030023101ex99-1.htm",
    "PolyPid management's discussion for the six months to 2026-06-30, 6-K exhibit 99.2, 2026-08-12: https://www.sec.gov/Archives/edgar/data/1611842/000121390026088439/ea030023101ex99-2.htm",
    "PolyPid 6-K, 2026-07-21 (Azurity agreement): https://www.sec.gov/Archives/edgar/data/1611842/000121390026079808/ea0298559-6k_polypid.htm",
    "License and Supply Agreement with Azurity dated 2026-07-17, exhibit 10.1 to the 6-K of 2026-07-21: https://www.sec.gov/Archives/edgar/data/1611842/000121390026079808/ea029855901ex10-1.htm",
    "PolyPid 6-K exhibit 99.1, 2026-06-01 (submission completed): https://www.sec.gov/Archives/edgar/data/1611842/000121390026063169/ea029288201ex99-1.htm",
    "PolyPid 6-K exhibit 99.1, 2026-05-13 (Q1 2026 update): https://www.sec.gov/Archives/edgar/data/1611842/000121390026055449/ea029031501ex99-1.htm",
    "PolyPid 6-K exhibit 99.1, 2026-03-31 (submission started): https://www.sec.gov/Archives/edgar/data/1611842/000121390026036923/ea028428801ex99-1.htm",
    "PolyPid 6-K exhibit 99.1, 2026-10-01 (EMA validation): https://www.sec.gov/Archives/edgar/data/1611842/000121390026105492/ea030731601ex99-1.htm",
    "PolyPid 6-K exhibit 99.1, 2026-10-01 (ADVANZ termination): https://www.sec.gov/Archives/edgar/data/1611842/000121390026105474/ea030731501ex99-1.htm",
    "PolyPid 20-F for FY2025, filed 2026-02-25: https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/ea0276727-20f_polypid.htm",
    "PolyPid 20-F for FY2024, filed 2025-02-26: https://www.sec.gov/Archives/edgar/data/1611842/000121390025017412/ea0231533-20f_polypid.htm",
    "PolyPid 6-K exhibit 99.1, 2025-12-03 (pre-NDA minutes): https://www.sec.gov/Archives/edgar/data/1611842/000121390025117581/ea026831301ex99-1_polypid.htm",
    "PolyPid 6-K exhibit 99.1, 2025-09-16 (Israeli GMP inspection): https://www.sec.gov/Archives/edgar/data/1611842/000121390025087942/ea025753001ex99-1_polypid.htm",
    "PolyPid 6-K exhibit 99.1, 2025-06-09 (SHIELD II topline): https://www.sec.gov/Archives/edgar/data/1611842/000121390025052320/ea024508901ex99-1_polypid.htm",
    "PolyPid 6-K exhibit 99.1, 2024-12-26 (interim analysis): https://www.sec.gov/Archives/edgar/data/1611842/000121390024112468/ea022575301ex99-1_polypid.htm",
    "PolyPid 6-K exhibit 99.1, 2023-01-24 (FDA Type D feedback): https://www.sec.gov/Archives/edgar/data/1611842/000121390023004609/ea172110ex99-1_polypid.htm",
    "PolyPid 6-K exhibit 99.1, 2022-09-02 (SHIELD I topline): https://www.sec.gov/Archives/edgar/data/1611842/000121390022053474/ea165323ex99-1_polypid.htm",
    "PolyPid Q2 2026 results call transcript, 2026-08-12: https://www.fool.com/earnings/call-transcripts/2026/08/19/polypid-pypd-q2-2026-earnings-call-transcript/",
    "PolyPid at the Lytham Partners investor conference, 2026-09-29 (transcript summary): https://www.investing.com/news/transcripts/polypid-at-lytham-partners-fda-decision-nears-for-lead-drug-93CH-4923807",
    "Zmora et al., SHIELD 1 randomized clinical trial, International Journal of Surgery 2024: https://pmc.ncbi.nlm.nih.gov/articles/PMC11486998/",
    "FDA guidance, Qualified Infectious Disease Product Designation Questions and Answers: https://www.fda.gov/media/148480/download",
    "21 CFR 314.106, foreign data: https://www.ecfr.gov/current/title-21/section-314.106",
    "Federal Register, notices mentioning the Antimicrobial Drugs Advisory Committee, searched 2026-10-05: https://www.federalregister.gov/documents/search?conditions%5Bterm%5D=%22Antimicrobial+Drugs+Advisory+Committee%22",
    "Hogan Lovells, 2026-09-16, on FDA's statement of 2026-09-02 about trials outside the US: https://www.hlc.com/en/publications/fda-signals-more-inspections-scrutiny-of-clinical-trials-outside-the-us",
    "Prasad and Makary, N Engl J Med 2026;394(8):815-7, as summarised by AMR.Solutions on 2026-03-01: https://amr.solutions/2026/03/01/fda-one-pivotal-trial-confirmatory-evidence-is-default-expectation-for-approval/",
    "Al Jazeera, 2026-06-15: https://www.aljazeera.com/news/2026/6/15/iran-us-agree-tentative-deal-to-end-war-your-questions-answered",
    "SEC EDGAR filing list for PolyPid Ltd. (CIK 1611842), as of 2026-10-05: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001611842&type=&dateb=&owner=include&count=40"
  ],
  "zh": {
    "indication": "预防腹部结直肠手术患者的手术部位感染（关键试验入组的是切口超过 20 cm 的患者）",
    "key_factors": [
      {
        "factor": "关键试验达到主要终点和全部三个关键次要终点",
        "evidence": "SHIELD II 是一项随机 III 期试验，在择期结直肠切除术中比较标准治疗加 D-PLEX100 与单用标准治疗；主要分析针对切口超过 20 cm 的患者（405 例对 393 例）。主要终点是 30 天内切口感染、切口处再次干预或任何原因死亡的复合终点，发生率为 10.9%（95% CI 8.0 至 14.3）对 18.1%（95% CI 14.4 至 22.2），相差 -7.2 个百分点（95% CI -12.1 至 -2.3；p=0.0039）。单看由设盲的独立委员会判定的切口感染，为 3.8% 对 9.5%（相差 -5.8 个百分点，95% CI -9.3 至 -2.3；p=0.0013）。在全部 975 名随机入组患者（切口超过 7 cm）中，复合终点为 11.1% 对 17.4%（p=0.0047）；ASEPSIS 伤口评分超过 20 的患者比例为 2.0% 对 5.6%（p=0.0103）。截至 2026 年 10 月 5 日，公开资料未见 SHIELD II 经同行评议发表；以上数字出自申办方在试验注册库登记的结果。"
      },
      {
        "factor": "FDA 参与了试验设计，并事先同意一项关键试验可以足够",
        "evidence": "按公司的说法：2021 年 5 月，FDA 在 B 类会议上同意，只要结果充分，一项关键 III 期试验就足以支持结直肠手术适应症获批；2023 年 1 月，在第一项 III 期试验之后，FDA 表示其大切口人群的结果可以作为支持性证据，并建议再做一项研究，SHIELD II 可以充当这项研究；2023 年 5 月，FDA 同意了修订后的 SHIELD II 设计；在 2025 年 12 月 3 日公布的 pre-NDA 会议纪要中，FDA 同意现有临床资料看来足以支持 NDA 的提交和审评。第一项试验中的大切口分析本身就是应 FDA 的要求做的。D-PLEX100 拥有突破性疗法认定（2020 年 11 月）、快速通道资格和三项合格传染病产品（QIDP）认定。2026 年 2 月，FDA 领导层撰文称，一项充分且良好对照的试验加上确证性证据，如今是批准的默认依据。局限在于：FDA 的函件和会议纪要均未公开；pre-NDA 的措辞说的是资料能否提交并进入审评，而不是能否获批。"
      },
      {
        "factor": "申请受理时未被指出审评问题，也没有召开咨询委员会",
        "evidence": "PolyPid 于 2026 年 6 月 1 日宣布滚动提交全部完成。FDA 于 2026 年 7 月 27 日受理该申请，据公司称没有指出任何立卷审评问题。2026 年 11 月 28 日的 PDUFA 目标日期来自优先审评，但这一身份并不能说明 FDA 对数据的看法：法律规定，获得合格传染病产品（QIDP）认定的产品，其首个申请必须给予优先审评。公司没有宣布过针对该申请的咨询委员会会议，Federal Register 自 2026 年 6 月以来也没有刊登抗菌药物咨询委员会的会议通知。2026 年 8 月 12 日，首席执行官表示审评进行得有效而高效，与 FDA 已有多轮沟通。中期或后期审评会议的结果以及标签讨论均未见披露。2026 年 11 月 28 日是星期六，在感恩节之后两天，FDA 可能提前几天作出决定。"
      },
      {
        "factor": "更早的一项 III 期试验失败，成功的这项试验检验的是从中找出的亚组",
        "evidence": "第一项 III 期试验 SHIELD I（977 名患者，切口超过 10 cm）于 2022 年 9 月公布未达主要终点：9.3% 对 12.1%（相差 -2.8 个百分点，95% CI -6.7 至 1.0；p=0.152），切口感染为 6.2% 对 6.9%（p=0.62）。在预先设定、但未作多重性校正的分析中，423 名切口超过 20 cm 的患者里，主要终点事件为 212 例中 17 例（8.0%）对 211 例中 37 例（17.5%），p=0.0032。当时 SHIELD II 已按较宽的标准入组 200 多名患者，其中约 40 名为大切口；2023 年改为只入组切口超过 20 cm 的患者。用一项新的前瞻性试验去检验亚组结果是公认的确证方式，结果也得到重现。即便如此，整套证据仍是一项成功、一项失败，主要终点 p 值为 0.0039。SHIELD II 还对前 430 名患者做过一次揭盲的期中分析，此后样本量由最少 624 例增至 800 例。对照组没有使用安慰剂，手术团队知道分组；伤口评估者和判定委员会保持盲态。公司 2025 年度的年报与 2024 年度的不同，已不再介绍第一项试验。"
      },
      {
        "factor": "关键试验几乎没有在美国治疗的患者",
        "evidence": "SHIELD II 随机入组的 975 名患者中，在美国入组的只有 4 名。入组最多的是摩尔多瓦（246）、匈牙利（181）、塞尔维亚（135）、北马其顿（113）、罗马尼亚（104）、波斯尼亚和黑塞哥维那（68）和以色列（55）；975 人中有 973 人为白人。SHIELD I 的 977 名患者中有 37 名来自美国。FDA 对依靠境外数据的申请有专门规定，要求这些数据适用于美国人群和美国的医疗实践，并且 FDA 在认为必要时能够通过检查加以核实。随机化按地区和预防方案类型（包括口服抗生素加肠道准备）分层，但 4 名美国患者无法给出美国人群自身的疗效估计。2026 年 9 月 2 日，FDA 药品和生物制品两个中心的主任表示将加强对境外试验的检查。反过来看，FDA 在受理申请、未指出立卷问题时，已经知道患者是在哪些国家入组的。FDA 是否检查过试验中心，没有公开信息。"
      },
      {
        "factor": "D-PLEX100 没有带来更多严重伤害，死亡反而更少",
        "evidence": "在 SHIELD II 的安全性人群中（D-PLEX100 组 481 例，标准治疗组 493 例，随访 60 天），死亡 10 例（2.1%）对 19 例（3.9%），发生严重不良事件的患者为 75 例（15.6%）对 85 例（17.2%）；严重的术后伤口感染为 3 例对 10 例。SHIELD I 中死亡为 485 例中 16 例对 489 例中 17 例，严重不良事件为 478 例中 69 例对 498 例中 98 例。活性成分 doxycycline（多西环素）早已获批，申请部分依赖 FDA 此前对它的结论（505(b)(2) 途径）。每瓶 5 g 含 54.6 mg doxycycline，最多使用三瓶（163.8 mg）；公司称全身暴露极低。"
      },
      {
        "factor": "D-PLEX100 组报告的切口裂开更多",
        "evidence": "在 SHIELD II 中，非严重的切口裂开在 D-PLEX100 组 481 例中有 25 例（5.2%），标准治疗组 493 例中有 8 例（1.6%）；切口部位红斑为 65 例对 46 例，肿胀为 58 例对 45 例。严重的切口裂开（2 例对 2 例）和切口内脏脱出（2 例对 2 例）两组持平。在 SHIELD I 中，愈合不良为 478 例中 7 例对 498 例中 1 例，切口裂开为 6 例对 5 例。该产品会把带包衣的 β-磷酸三钙颗粒留在缝合后的切口内。这更像是需要写进标签的问题，而不像拒批的理由；公司称安全性良好，但 FDA 如何看待并未公开。FDA 在 2023 年曾向公司指出，预防感染的产品有可能被广泛使用。"
      },
      {
        "factor": "第一个商业化产品，由公司自有的无菌工厂生产，该厂从未获得 FDA 认可",
        "evidence": "PolyPid 没有任何已获批产品。D-PLEX100 是一种无菌粉末，手术时调成糊状使用，在公司位于以色列 Petah Tikva、租用的约 22,000 平方英尺的工厂生产。2026 年 7 月 17 日的许可协议写明，PolyPid 目前只获得以色列主管部门对临床试验用药生产的许可，没有 FDA 对商业化供货的授权；年报称，获批前工厂必须通过 FDA 的批准前检查。2026 年 8 月 12 日，首席执行官表示 FDA 已就审评期间预计进行的各项检查与公司沟通，但不愿透露日期，并称公司已在外部顾问协助下做过多次模拟检查。截至 2026 年 10 月 5 日，公开资料未见这次检查已经进行，更未见其结果。六个月的优先审评时限，留给公司在 11 月 28 日前答复检查发现的时间很少。一场涉及伊朗的地区战争从 2026 年 2 月 28 日持续到 2026 年 6 月 14 日宣布达成协议，正值申请提交期间；年报也提示敌对行动可能干扰运营。doxycycline 的供应商和合同生产商在公开文件中均未具名，公司称若干原材料依赖单一供应商。"
      },
      {
        "factor": "工厂在以色列监管机构的记录良好，工艺已于 2023 年完成验证",
        "evidence": "以色列卫生部于 2023 年 9 月完成对该工厂的 GMP 审计，未发现关键或主要缺陷；2025 年 9 月又完成一次，公司称这是连续第四次通过检查；根据欧盟与以色列的合格评定协议，这些审计在欧盟同样有效。三批工艺验证批次已于 2023 年 9 月完成并进入稳定性考察。申请中的生产和非临床部分于 2026 年 3 月 30 日率先提交，比临床部分早约两个月，FDA 审阅这部分的时间更充裕。管理层称，包括 Azurity 在内的潜在商业合作方曾到工厂做现场尽职调查。截至 2026 年 6 月 30 日，上市前库存为 140 万美元。不过，以色列的 GMP 证书不能代替 FDA 的检查。"
      },
      {
        "factor": "商业合作方在决定前已支付 3000 万美元，上市准备正在进行",
        "evidence": "2026 年 7 月 17 日，Azurity Pharmaceuticals 取得美国和加拿大的权利，签约时支付 1500 万美元，FDA 受理申请后再付 1500 万美元；另有最多约 3 亿美元取决于监管、开发和销售里程碑，美国上市目标定在 2027 年初。管理层称 Azurity 正在组建销售队伍，双方的联合上市团队已在运作。PolyPid 于 2026 年 9 月 14 日提交欧洲上市申请，EMA 已完成形式审查并受理。加上 Azurity 的付款，公司预计资金可支撑运营到 2028 年，审评期间不存在融资压力。2026 年 3 月以来的内部人申报只显示期权授予。另一方面，PolyPid 与 ADVANZ PHARMA 经双方同意终止了 2022 年的欧洲许可协议，于 2026 年 10 月 1 日公布；公司称这是寻找新合作方的机会。截至 2026 年 6 月 30 日的中期报表仍带有持续经营存疑的提示。"
      }
    ],
    "manufacturing_risk_why": "D-PLEX100 是 PolyPid 的第一个商业化产品，由公司自己在以色列 Petah Tikva 的无菌工厂生产（约 22,000 平方英尺；中期报表称之为中试生产厂）。产品剂型复杂：载有 doxycycline 的聚合物-脂质基质包覆在 β-磷酸三钙颗粒上，以 5 g 瓶装无菌粉末供应。截至 2026 年 7 月，该厂只获得以色列主管部门对临床试验用药的生产许可，没有 FDA 对商业化供货的授权；必须通过 FDA 的批准前检查。有利的方面：连续四次通过以色列卫生部的 GMP 检查（最近一次在 2025 年 9 月；2023 年的审计未发现关键或主要缺陷），三批工艺验证批次已于 2023 年 9 月完成，生产部分比临床部分早两个月提交。无法判断的部分：FDA 是否已检查该厂、结果如何（截至 2026 年 10 月 5 日公开资料未见）；doxycycline 和单一来源原材料由谁供应、其检查记录如何；Azurity 选定的包装承包商在申请中处于什么位置。年报还提到，以色列方面早先对一家合同生产商的 D-PLEX100 生产工艺做过审计，曾提出关键缺陷，公司称已经解决。",
    "what_would_change_my_mind": [
      "上调：PolyPid 或 FDA 披露 Petah Tikva 工厂的批准前检查已经完成且没有观察项，或观察项已被 FDA 认可为解决。",
      "上调：公司披露已与 FDA 讨论标签或上市后承诺，这通常是审评走向批准的迹象。",
      "下调：工厂或供应商收到含重要观察项的 Form 483，或有消息称检查无法在 PDUFA 目标日期前完成，包括因以色列安全局势所致。",
      "下调：FDA 召开咨询委员会、质疑东欧数据是否适用于美国的医疗实践，或在入组人数多的试验中心发现数据可靠性问题。",
      "改期而非判否：FDA 因重大补充材料延后 PDUFA 目标日期；届时将按新日期重新评估。",
      "作废而非判否：PolyPid 在 FDA 作出决定前撤回申请。"
    ]
  },
  "recorded_at": "2026-10-05T08:21:32+00:00"
}